Provided by Tiger Fintech (Singapore) Pte. Ltd.

Y-mAbs Therapeutics, Inc.

4.10
-0.0300-0.73%
Post-market: 4.100.00000.00%18:54 EDT
Volume:108.64K
Turnover:442.40K
Market Cap:185.39M
PE:-6.12
High:4.12
Open:4.09
Low:3.94
Close:4.13
Loading ...

Stock Track | Y-mAbs Stock Plunges Over 11% as Q3 Earnings Miss Estimates on Higher Costs

Stock Track
·
08 Nov 2024

Stock Track | Y-mAbs Stock Plunges 7% as Q3 Earnings Disappoint on Higher Costs

Stock Track
·
08 Nov 2024

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates

Zacks
·
08 Nov 2024

Y-mAbs Anticipates 2024 Total Net Revenues Of $87M-$95M Vs. Consensus Of $91.67M

Benzinga
·
08 Nov 2024

BRIEF-Y-mAbs Reports Q3 2024 Financial Results And Recent Corporate Developments

Reuters
·
08 Nov 2024

BRIEF-Y-mAbs Therapeutics Q3 Net Income USD -7 Million Vs. IBES Estimate USD -7.42 Million

Reuters
·
08 Nov 2024

Y-mAbs Therapeutics Q3 Product Revenue USD 18.5 Million

THOMSON REUTERS
·
08 Nov 2024

Y-mAbs Therapeutics - Reiterates Full Year 2024 Guidance

THOMSON REUTERS
·
08 Nov 2024

Y-mAbs Therapeutics Inc: Qtrly Total Net REV $18.5 Mln

THOMSON REUTERS
·
08 Nov 2024

Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments

GlobeNewswire
·
08 Nov 2024

Y-mAbs Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview

Reuters
·
06 Nov 2024

Wave Life Sciences (WVE) Expected to Beat Earnings Estimates: Should You Buy?

Zacks
·
05 Nov 2024

Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for Danyelza® (Naxitamab-Gqgk) in Japan

THOMSON REUTERS
·
04 Nov 2024

Y-mAbs Therapeutics Inc - Nobelpharma to Handle Regulatory and Commercialization of Danyelza in Japan

THOMSON REUTERS
·
04 Nov 2024

Y-mAbs Therapeutics Inc - to Receive $2 Mln Upfront, up to $31 Mln in Milestone Payments

THOMSON REUTERS
·
04 Nov 2024

Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan

GlobeNewswire
·
04 Nov 2024

Will Y-mAbs Therapeutics, Inc. (YMAB) Report Negative Earnings Next Week? What You Should Know

Zacks
·
01 Nov 2024

Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights

Benzinga
·
31 Oct 2024